Author Index Volume 3 (2016)
The issue number is given in front of the pagination
Aartsma-Rus, A., see Hulsker, M. (1) 77–90
Ahmed, R., see Argov, Z. (1) 49–66
Alameddine, H.S. and J.E. Morgan, Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal Muscles (4) 455–473
Allamand, V., see Cruz, S. (2) 267–274
Almeida-Souza, L., see Bouhy, D. (2) 183–200
Anderson, K.N., see West, S.D. (4) 529–537
Antonini, G., see Garibaldi, M. (1) 111–114
Argov, Z., Y. Caraco, H. Lau, A. Pestronk, P.B. Shieh, A. Skrinar, T. Koutsoukos, R. Ahmed, J. Martinisi and E. Kakkis, Aceneuramic Acid Extended Release Administration Maintains Upper Limb Muscle Strength in a 48-week Study of Subjects with GNE Myopathy: Results from a Phase 2, Randomized, Controlled Study (1) 49–66
Arvanitidis, A., K. Henriksen, M.A. Karsdal and A. Nedergaard, Neo-epitope Peptides as Biomarkers of Disease Progression for Muscular Dystrophies and Other Myopathies (3) 333–346
Atalaia, A., see West, S.D. (4) 529–537
Audebert-Bellanger, S., see Grotto, S. (4) 487–495
Auranen, M., see Ylikallio, E. (4) 475–485
Azibani, F., see Ziat, E. (4) 497–510
Badders, N.M., see Lanman, T.A. (1) 121–125
Bakar, D., see Lanman, T.A. (1) 121–125
Barghout, V., see Price, M.A. (1) 67–75
Bartsakoulia, M., J.S. Müller, A. Gomez-Duran, P.Y.W. Man, V. Boczonadi and R. Horvath, Cysteine Supplementation May be Beneficial in a Subgroup of Mitochondrial Translation Deficiencies (3) 363–379
Baudin, P.-Y., see Carlier, P.G. (1) 1–28
Baudouin, S.V., see West, S.D. (4) 529–537
Becane, H.-M., see Marey, I. (2) 227–245
Behin, A., see Marey, I. (2) 227–245
Benveniste, O., see Price, M.A. (1) 67–75
Berrios, R.A., see Ramos, E. (2) 261–266
Bertini, E., see Garibaldi, M. (1) 111–114
Bertorini, T.E., see Punetha, J. (2) 209–225
Bertrand, A.T., see Ziat, E. (4) 497–510
Beuvin, M., see Ziat, E. (4) 497–510
Bian, A., see Posner, A.D. (1) 91–99
Biasini, F., see Rodolico, C. (3) 413–418
Bierry, G., see Rudolf, G. (2) 275–281
Boczonadi, V., see Bartsakoulia, M. (3) 363–379
Böhm, J., see Garibaldi, M. (1) 111–114
Bonne, G., see Ziat, E. (4) 497–510
Bönnemann, C.G., see Punetha, J. (2) 209–225
Bott, L.C., see Lanman, T.A. (1) 121–125
Bouhy, D., T. Geuens, V. De Winter, L. Almeida-Souza, I. Katona, J. Weis, T. Hochepied, S. Goossens, J.J. Haigh, S. Janssens and V. Timmerman, Characterization of New Transgenic Mouse Models for Two Charcot-Marie-Tooth-Causing HspB1 Mutations using the Rosa26 Locus (2) 183–200
Boyer, F.C., see Marey, I. (2) 227–245
Brandom, B.W., see Butala, B.N. (1) 115–119
Buchkremer, S., J.A.G. Coraspe, J. Weis and A. Roos, Sil1-Mutant Mice Elucidate Chaperone Function in Neurological Disorders (2) 169–181
Burke, A., see Lanman, T.A. (1) 121–125
Burnette, W.B., see Posner, A.D. (1) 91–99
Bushby, K., see Vry, J. (4) 517–527
Butala, B.N., A. Kang, J. Guron and B.W. Brandom, Long term oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual (1) 115–119
Butchbach, M.E.R., see Edwards, J.D. (4) 511–515
Campbell, C., see Prasad, M. (3) 405–412
Caraco, Y., see Argov, Z. (1) 49–66
Carlier, P.G., B. Marty, O. Scheidegger, P. Loureiro de Sousa, P.-Y. Baudin, E. Snezhko and D. Vlodavets, Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials (1) 1–28
Carver, M.P., J.S. Charleston, C. Shanks, J. Zhang, M. Mense, A.K. Sharma, H. Kaur and P. Sazani, Toxicological Characterization of Exon Skipping Phosphorodiamidate Morpholino Oligomers (PMOs) in Non-human Primates (3) 381–393
Castets, P., S. Frank, M. Sinnreich and M.A. Rüegg, “Get the Balance Right”: Pathological Significance of Autophagy Perturbation in Neuromuscular Disorders (2) 127–155
Chadwick, J.A., see Lowe, J. (3) 395–404
Chamova, T., see Vry, J. (4) 517–527
Chardon, J.W., B.J. Jasmin, R. Kothary and R.J. Parks, Report on the 3rd Ottawa International Conference on Neuromuscular Biology, Disease and Therapy – September 24–26, 2015, Ottawa, Canada (3) 431–442
Charleston, J.S., see Carver, M.P. (3) 381–393
Chelly, J., see Marey, I. (2) 227–245
Christopher-Stine, L., see Price, M.A. (1) 67–75
Ciranni, A., see Rodolico, C. (3) 413–418
Clarke, N.F., see Punetha, J. (2) 209–225
Claustres, M., see Marey, I. (2) 227–245
Conde, J.G., see Ramos, E. (2) 261–266
Coraspe, J.A.G., see Buchkremer, S. (2) 169–181
Corbett, A., see Price, M.A. (1) 67–75
Cortes-Vicente, E., see Cruz, S. (2) 267–274
Cossee, M., see Marey, I. (2) 227–245
Crowe, K.E., G. Shao, K.M. Flanigan and P.T. Martin, N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy (2) 247–260
Cruz, S., S. Figueroa-Bonaparte, E. Gallardo, A. de Becdelièvre, C. Gartioux, V. Allamand, P. Piñol, M.A.R. Garcia, C. Jiménez-Mallebriera, J. Llauger, L. González-Rodríguez, E. Cortes-Vicente, I. Illa and J. Díaz-Manera, Bethlem Myopathy Phenotypes and Follow Up: Description of 8 Patients at the Mildest End of the Spectrum (2) 267–274
Cuisset, J.-M., see Grotto, S. (4) 487–495
de Becdelièvre, A., see Cruz, S. (2) 267–274
de los Angeles Beytía, M., see Vry, J. (4) 517–527
de Visser, M., see Price, M.A. (1) 67–75
De Winter, V., see Bouhy, D. (2) 183–200
Deburgrave, N., see Marey, I. (2) 227–245
DeMuro, C., see Price, M.A. (1) 67–75
Denning, C., see Kalra, S. (3) 309–332
Desguerre, I., see Grotto, S. (4) 487–495
Desguerre, I., see Marey, I. (2) 227–245
Díaz-Manera, J., see Cruz, S. (2) 267–274
Doerken, S., see Vry, J. (4) 517–527
Donkervoort, S., see Punetha, J. (2) 209–225
Drunat, S., see Grotto, S. (4) 487–495
Echaniz-Laguna, A., see Rudolf, G. (2) 275–281
Echigoya, Y., see Rodrigues, M. (1) 29–48
Edwards, J.D. and M.E.R. Butchbach, Effect of the Butyrate Prodrug Pivaloyloxymethyl Butyrate (AN9) on a Mouse Model for Spinal Muscular Atrophy (4) 511–515
Eichinger, K., K. Odrzywolski, J. Sowden and D.N. Herrmann, Patient Reported Falls and Balance Confidence in Individuals with Charcot-Marie-Tooth Disease (2) 289–292
Evilä, A., see Papadimas, G.K. (2) 283–288
Evilä, A., see Rudolf, G. (2) 275–281
Eymard, B., see Marey, I. (2) 227–245
Fattori, F., see Garibaldi, M. (1) 111–114
Fauré, J., see Marty, I. (4) 443–453
Faure, P., see Grotto, S. (4) 487–495
Ferrer, X., see Marey, I. (2) 227–245
Figueroa-Bonaparte, S., see Cruz, S. (2) 267–274
Fischbeck, K.H., see Lanman, T.A. (1) 121–125
Flanigan, K.M., see Crowe, K.E. (2) 247–260
Floyd, K.T., see Lowe, J. (3) 395–404
Flurin, V., see Grotto, S. (4) 487–495
Frank, S., see Castets, P. (2) 127–155
Frébourg, T., see Grotto, S. (4) 487–495
Fukada, S., see Rodrigues, M. (1) 29–48
Furlong, M.J., see Mulroy, E. (3) 419–423
Gallardo, E., see Cruz, S. (2) 267–274
Garami, M., see Vry, J. (4) 517–527
Garcia, L., see Goyenvalle, A. (2) 157–167
Garcia, M.A.R., see Cruz, S. (2) 267–274
Garibaldi, M., J. Böhm, F. Fattori, C. Koch, C. Surace, P. Ottaviani, F. Laschena, J. Laporte, E. Bertini, G. Antonini and N.B. Romero, Novel Dominant Mutation in BIN1 Gene Causing Mild Centronuclear Myopathy Revealed by Myalgias and CK Elevation (1) 111–114
Gartioux, C., see Cruz, S. (2) 267–274
Geuens, T., see Bouhy, D. (2) 183–200
Ghaoui, R., see Punetha, J. (2) 209–225
Giri, M., see Punetha, J. (2) 209–225
Girlanda, P., see Rodolico, C. (3) 413–418
Gleeson, S., see Mulroy, E. (3) 419–423
Gómez, O., see Ramos, E. (2) 261–266
Gomez-Duran, A., see Bartsakoulia, M. (3) 363–379
Gomez-Sanchez, C.E., see Lowe, J. (3) 395–404
Gomez-Sanchez, E.P., see Lowe, J. (3) 395–404
González-Rodríguez, L., see Cruz, S. (2) 267–274
Goossens, S., see Bouhy, D. (2) 183–200
Goyenvalle, A., C. Leumann and L. Garcia, Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides (2) 157–167
Gramsch, K., see Vry, J. (4) 517–527
Grebille, A.-G., see Grotto, S. (4) 487–495
Grotto, S., J.-M. Cuisset, S. Marret, S. Drunat, P. Faure, S. Audebert-Bellanger, I. Desguerre, V. Flurin, A.-G. Grebille, A.-M. Guerrot, H. Journel, G. Morin, G. Plessis, S. Renolleau, J. Roume, B. Simon-Bouy, R. Touraine, M. Willems, T. Frébourg, E. Verspyck and P. Saugier-Veber, Type 0 Spinal Muscular Atrophy: Further Delineation of Prenatal and Postnatal Features in 16 Patients (4) 487–495
Grunseich, C., see Lanman, T.A. (1) 121–125
Guergueltcheva, V., see Vry, J. (4) 517–527
Guerrot, A.-M., see Grotto, S. (4) 487–495
Guron, J., see Butala, B.N. (1) 115–119
Hackman, P., see Rudolf, G. (2) 275–281
Hackman, P., see Savarese, M. (3) 293–308
Haigh, J.J., see Bouhy, D. (2) 183–200
Harmison, G.G., see Lanman, T.A. (1) 121–125
Hausmanowa-Petrusewicz, I., see Punetha, J. (2) 209–225
Heatwole, C., see Hunter, M. (3) 425–429
Henriksen, K., see Arvanitidis, A. (3) 333–346
Herczegfalvi, Á., see Vry, J. (4) 517–527
Herrmann, D.N., see Eichinger, K. (2) 289–292
Hicks, R., see Prasad, M. (3) 405–412
Hilton-Jones, D., see Price, M.A. (1) 67–75
Hochepied, T., see Bouhy, D. (2) 183–200
Hoffman, E.P., see Punetha, J. (2) 209–225
Horvath, R., see Bartsakoulia, M. (3) 363–379
Hughes, J., see West, S.D. (4) 529–537
Hulsker, M., I. Verhaart, L. van Vliet, A. Aartsma-Rus and M. van Putten, Accurate Dystrophin Quantification in Mouse Tissue; Identification of New and Evaluation of Existing Methods (1) 77–90
Hunter, M., C. Heatwole, E. Luebbe and N.E. Johnson, What Matters Most: A Perspective From Adult Spinal Muscular Atrophy Patients (3) 425–429
Illa, I., see Cruz, S. (2) 267–274
Ito, N., N. Shimizu, H. Tanaka and S. Takeda, Enhancement of Satellite Cell Transplantation Efficiency by Leukemia Inhibitory Factor (2) 201–207
Janssen, P.M.L., see Lowe, J. (3) 395–404
Janssens, S., see Bouhy, D. (2) 183–200
Jasmin, B.J., see Chardon, J.W. (3) 431–442
Jiménez-Mallebriera, C., see Cruz, S. (2) 267–274
Joe, G.O., see Lanman, T.A. (1) 121–125
Johnson, N.E., see Hunter, M. (3) 425–429
Journel, H., see Grotto, S. (4) 487–495
Kadakia, F.K., see Lowe, J. (3) 395–404
Kakkis, E., see Argov, Z. (1) 49–66
Kalra, S., F. Montanaro and C. Denning, Can Human Pluripotent Stem Cell-Derived Cardiomyocytes Advance Understanding of Muscular Dystrophies? (3) 309–332
Kaminska, A., see Vry, J. (4) 517–527
Kang, A., see Butala, B.N. (1) 115–119
Kararizou, E., see Papadimas, G.K. (2) 283–288
Karcagi, V., see Vry, J. (4) 517–527
Karsdal, M.A., see Arvanitidis, A. (3) 333–346
Katona, I., see Bouhy, D. (2) 183–200
Kaur, H., see Carver, M.P. (3) 381–393
Kesari, A., see Punetha, J. (2) 209–225
Kirschner, J., see Vry, J. (4) 517–527
Kissel, J.T., see Price, M.A. (1) 67–75
Kiuru-Enari, S., see Ylikallio, E. (4) 475–485
Koch, C., see Garibaldi, M. (1) 111–114
Kokkinis, A., see Lanman, T.A. (1) 121–125
Kostera-Pruszczyk, A., see Vry, J. (4) 517–527
Kothary, R., see Chardon, J.W. (3) 431–442
Kousi, M., see Ylikallio, E. (4) 475–485
Koutsoukos, T., see Argov, Z. (1) 49–66
Laforet, P., see Marey, I. (2) 227–245
Lammens, M., see van der Sluijs, B.M. (1) 101–109
Lamminen, A., see Ylikallio, E. (4) 475–485
Lanman, T.A., D. Bakar, N.M. Badders, A. Burke, A. Kokkinis, J.A. Shrader, G.O. Joe, A.B. Schindler, L.C. Bott, G.G. Harmison, J.P. Taylor, K.H. Fischbeck and C. Grunseich, Sexual Reassignment Fails to Prevent Kennedy’s Disease (1) 121–125
Lannes, B., see Rudolf, G. (2) 275–281
Laporte, J., see Garibaldi, M. (1) 111–114
Laschena, F., see Garibaldi, M. (1) 111–114
Lau, H., see Argov, Z. (1) 49–66
Lehesjoki, A.-E., see Ylikallio, E. (4) 475–485
Leturcq, F., see Marey, I. (2) 227–245
Leumann, C., see Goyenvalle, A. (2) 157–167
Llauger, J., see Cruz, S. (2) 267–274
Lloyd, T.E., see Price, M.A. (1) 67–75
Lochmüller, H., see Vry, J. (4) 517–527
Lochmüller, H., see West, S.D. (4) 529–537
Löfberg, M., see Ylikallio, E. (4) 475–485
Loureiro de Sousa, P., see Carlier, P.G. (1) 1–28
Lowe, J., K.T. Floyd, N. Rastogi, E.J. Schultz, J.A. Chadwick, S.A. Swager, J.G. Zins, F.K. Kadakia, S. Smart, E.P. Gomez-Sanchez, C.E. Gomez-Sanchez, S.V. Raman, P.M.L. Janssen and J.A. Rafael-Fortney, Similar Efficacy from Specific and Non-Specific Mineralocorticoid Receptor Antagonist Treatment of Muscular Dystrophy Mice (3) 395–404
Luebbe, E., see Hunter, M. (3) 425–429
Lundberg, I.E., see Price, M.A. (1) 67–75
Lusakowska, A., see Vry, J. (4) 517–527
MacKay, M., see Prasad, M. (3) 405–412
Mahjneh, I., see Ylikallio, E. (4) 475–485
Mamchaoui, K., see Ziat, E. (4) 497–510
Man, P.Y.W., see Bartsakoulia, M. (3) 363–379
Manta, P., see Papadimas, G.K. (2) 283–288
Marey, I., R.B. Yaou, N. Deburgrave, A. Vasson, J. Nectoux, F. Leturcq, B. Eymard, P. Laforet, A. Behin, T. Stojkovic, M. Mayer, V. Tiffreau, I. Desguerre, F.C. Boyer, A. Nadaj-Pakleza, X. Ferrer, K. Wahbi, H.-M. Becane, M. Claustres, J. Chelly and M. Cossee, Non Random Distribution of DMD Deletion Breakpoints and Implication of Double Strand Breaks Repair and Replication Error Repair Mechanisms (2) 227–245
Marini-Bettolo, C., see West, S.D. (4) 529–537
Markham, L.W., see Posner, A.D. (1) 91–99
Marret, S., see Grotto, S. (4) 487–495
Martin, P.T., see Crowe, K.E. (2) 247–260
Martinisi, J., see Argov, Z. (1) 49–66
Marty, B., see Carlier, P.G. (1) 1–28
Marty, I. and J. Fauré, Excitation-Contraction Coupling Alterations in Myopathies (4) 443–453
Mastaglia, F., see Price, M.A. (1) 67–75
Mayer, M., see Marey, I. (2) 227–245
Mense, M., see Carver, M.P. (3) 381–393
Messina, S., see Rodolico, C. (3) 413–418
Meyrick, J., see Walklet, E. (3) 347–362
Montanaro, F., see Kalra, S. (3) 309–332
Morgan, J.E., see Alameddine, H.S. (4) 455–473
Morin, G., see Grotto, S. (4) 487–495
Moss, T., see Walklet, E. (3) 347–362
Mozaffar, T., see Price, M.A. (1) 67–75
Mrazova, L., see Vry, J. (4) 517–527
Müller, J.S., see Bartsakoulia, M. (3) 363–379
Mulroy, E., S. Gleeson and M.J. Furlong, Stress-Induced Ketoacidosis in Spinal Muscular Atrophy: An Under-Recognized Complication (3) 419–423
Muse, K., see Walklet, E. (3) 347–362
Musumeci, O., see Rodolico, C. (3) 413–418
Muurinen, T., see Ylikallio, E. (4) 475–485
Nadaj-Pakleza, A., see Marey, I. (2) 227–245
Nectoux, J., see Marey, I. (2) 227–245
Nedergaard, A., see Arvanitidis, A. (3) 333–346
Needham, M., see Price, M.A. (1) 67–75
Nelson, I., see Ziat, E. (4) 497–510
Nguyen, C.-T., see Prasad, M. (3) 405–412
North, K.N., see Punetha, J. (2) 209–225
O’Grady, G.L., see Punetha, J. (2) 209–225
Oates, E.C., see Punetha, J. (2) 209–225
Odrzywolski, K., see Eichinger, K. (2) 289–292
Ottaviani, P., see Garibaldi, M. (1) 111–114
Paetau, A., see Ylikallio, E. (4) 475–485
Papadimas, G.K., A. Evilä, C. Papadopoulos, E. Kararizou, P. Manta and B. Udd, GNE-Myopathy in a Greek Romani Family with Unusual Calf Phenotype and Protein Aggregation Pathology (2) 283–288
Papadopoulos, C., see Papadimas, G.K. (2) 283–288
Pardo, S., see Ramos, E. (2) 261–266
Parisi, D., see Rodolico, C. (3) 413–418
Parks, R.J., see Chardon, J.W. (3) 431–442
Pavlovska, L., see Vry, J. (4) 517–527
Penttilä, S., see Rudolf, G. (2) 275–281
Pestronk, A., see Argov, Z. (1) 49–66
Piirilä, P., see Ylikallio, E. (4) 475–485
Piñol, P., see Cruz, S. (2) 267–274
Plessis, G., see Grotto, S. (4) 487–495
Plotz, P.H., see Punetha, J. (2) 209–225
Portaro, S., see Rodolico, C. (3) 413–418
Posner, A.D., J.H. Soslow, W.B. Burnette, A. Bian, A. Shintani, D.B. Sawyer and L.W. Markham, The Correlation of Skeletal and Cardiac Muscle Dysfunction in Duchenne Muscular Dystrophy (1) 91–99
Prasad, M., R. Hicks, M. MacKay, C.-T. Nguyen and C. Campbell, Developmental Milestones and Quality of Life Assessment in a Congenital Myotonic Dystrophy Cohort (3) 405–412
Price, M.A., V. Barghout, O. Benveniste, L. Christopher-Stine, A. Corbett, M. de Visser, D. Hilton-Jones, J.T. Kissel, T.E. Lloyd, I.E. Lundberg, F. Mastaglia, T. Mozaffar, M. Needham, J. Schmidt, K. Sivakumar, C. DeMuro and B.S. Tseng, Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA (1) 67–75
Punetha, J., A. Kesari, P. Uapinyoying, M. Giri, N.F. Clarke, L.B. Waddell, K.N. North, R. Ghaoui, G.L. O’Grady, E.C. Oates, S.A. Sandaradura, C.G. Bönnemann, S. Donkervoort, P.H. Plotz, E.C. Smith, C. Tesi-Rocha, T.E. Bertorini, M.A. Tarnopolsky, B. Reitter, I. Hausmanowa-Petrusewicz and E.P. Hoffman, Targeted Re-Sequencing Emulsion PCR Panel for Myopathies: Results in 94 Cases (2) 209–225
Rafael-Fortney, J.A., see Lowe, J. (3) 395–404
Rahbek, J., see Vry, J. (4) 517–527
Raman, S.V., see Lowe, J. (3) 395–404
Ramos, E., J.G. Conde, R.A. Berrios, S. Pardo, O. Gómez and M.F.M. Rodríguez, Prevalence and Genetic Profile of Duchene and Becker Muscular Dystrophy in Puerto Rico (2) 261–266
Rastogi, N., see Lowe, J. (3) 395–404
Raz, V., see van der Sluijs, B.M. (1) 101–109
Reitter, B., see Punetha, J. (2) 209–225
Renolleau, S., see Grotto, S. (4) 487–495
Rodger, S., see Vry, J. (4) 517–527
Rodolico, C., D. Parisi, S. Portaro, F. Biasini, S. Sinicropi, A. Ciranni, A. Toscano, S. Messina, O. Musumeci, G. Vita and P. Girlanda, Myasthenia Gravis: Unusual Presentations and Diagnostic Pitfalls (3) 413–418
Rodrigues, M., Y. Echigoya, S. Fukada and T. Yokota, Current Translational Research and Murine Models For Duchenne Muscular Dystrophy (1) 29–48
Rodríguez, M.F.M., see Ramos, E. (2) 261–266
Romero, N.B., see Garibaldi, M. (1) 111–114
Roos, A., see Buchkremer, S. (2) 169–181
Roume, J., see Grotto, S. (4) 487–495
Rudolf, G., T. Suominen, S. Penttilä, P. Hackman, A. Evilä, B. Lannes, A. Echaniz-Laguna, G. Bierry, C. Tranchant and B. Udd, Homozygosity of the Dominant Myotilin c.179C>T (p.Ser60Phe) Mutation Causes a More Severe and Proximal Muscular Dystrophy (2) 275–281
Rüegg, M.A., see Castets, P. (2) 127–155
Salmi, T., see Ylikallio, E. (4) 475–485
Sandaradura, S.A., see Punetha, J. (2) 209–225
Sarparanta, J., see Savarese, M. (3) 293–308
Saugier-Veber, P., see Grotto, S. (4) 487–495
Savarese, M., J. Sarparanta, A. Vihola, B. Udd and P. Hackman, Increasing Role of Titin Mutations in Neuromuscular Disorders (3) 293–308
Sawyer, D.B., see Posner, A.D. (1) 91–99
Sazani, P., see Carver, M.P. (3) 381–393
Scheidegger, O., see Carlier, P.G. (1) 1–28
Schindler, A.B., see Lanman, T.A. (1) 121–125
Schmidt, J., see Price, M.A. (1) 67–75
Schröder, C.D., see van Groenestijn, A.C. (4) 539–544
Schultz, E.J., see Lowe, J. (3) 395–404
Shanks, C., see Carver, M.P. (3) 381–393
Shao, G., see Crowe, K.E. (2) 247–260
Sharma, A.K., see Carver, M.P. (3) 381–393
Shieh, P.B., see Argov, Z. (1) 49–66
Shimizu, N., see Ito, N. (2) 201–207
Shintani, A., see Posner, A.D. (1) 91–99
Shrader, J.A., see Lanman, T.A. (1) 121–125
Simon-Bouy, B., see Grotto, S. (4) 487–495
Sinicropi, S., see Rodolico, C. (3) 413–418
Sinnreich, M., see Castets, P. (2) 127–155
Sivakumar, K., see Price, M.A. (1) 67–75
Skrinar, A., see Argov, Z. (1) 49–66
Smart, S., see Lowe, J. (3) 395–404
Smith, E.C., see Punetha, J. (2) 209–225
Snezhko, E., see Carlier, P.G. (1) 1–28
Soslow, J.H., see Posner, A.D. (1) 91–99
Sowden, J., see Eichinger, K. (2) 289–292
Spuler, S., see Ziat, E. (4) 497–510
Steffensen, B.F., see Vry, J. (4) 517–527
Stojkovic, T., see Marey, I. (2) 227–245
Strenkova, J., see Vry, J. (4) 517–527
Suominen, T., see Rudolf, G. (2) 275–281
Surace, C., see Garibaldi, M. (1) 111–114
Swager, S.A., see Lowe, J. (3) 395–404
Takeda, S., see Ito, N. (2) 201–207
Tanaka, H., see Ito, N. (2) 201–207
Tarnopolsky, M.A., see Punetha, J. (2) 209–225
Tassoni, A., see Vry, J. (4) 517–527
Taylor, J.P., see Lanman, T.A. (1) 121–125
Tesi-Rocha, C., see Punetha, J. (2) 209–225
Thompson, R., see Vry, J. (4) 517–527
Tiffreau, V., see Marey, I. (2) 227–245
Timmerman, V., see Bouhy, D. (2) 183–200
Toscano, A., see Rodolico, C. (3) 413–418
Touraine, R., see Grotto, S. (4) 487–495
Tournev, I., see Vry, J. (4) 517–527
Tranchant, C., see Rudolf, G. (2) 275–281
Träskelin, A.-L., see Ylikallio, E. (4) 475–485
Tseng, B.S., see Price, M.A. (1) 67–75
Uapinyoying, P., see Punetha, J. (2) 209–225
Udd, B., see Papadimas, G.K. (2) 283–288
Udd, B., see Rudolf, G. (2) 275–281
Udd, B., see Savarese, M. (3) 293–308
van den Berg, L.H., see van Groenestijn, A.C. (4) 539–544
van den Heuvel, L.P., see van der Sluijs, B.M. (1) 101–109
van der Sluijs, B.M., V. Raz, M. Lammens, L.P. van den Heuvel, N.C. Voermans and B.G.M. van Engelen, Intranuclear Aggregates Precede Clinical Onset in Oculopharyngeal Muscular Dystrophy (1) 101–109
van Engelen, B.G.M., see van der Sluijs, B.M. (1) 101–109
van Groenestijn, A.C., O. Verschuren, C.D. Schröder, L.H. van den Berg and J.M.A. Visser-Meily, The Åstrand-Ryhming Test is not a Feasible Measure in Ambulatory Patients with Amyotrophic Lateral Sclerosis (4) 539–544
van Putten, M., see Hulsker, M. (1) 77–90
van Vliet, L., see Hulsker, M. (1) 77–90
Vasson, A., see Marey, I. (2) 227–245
Verhaart, I., see Hulsker, M. (1) 77–90
Verschuren, O., see van Groenestijn, A.C. (4) 539–544
Verspyck, E., see Grotto, S. (4) 487–495
Vihola, A., see Savarese, M. (3) 293–308
Visser-Meily, J.M.A., see van Groenestijn, A.C. (4) 539–544
Vita, G., see Rodolico, C. (3) 413–418
Vlodavets, D., see Carlier, P.G. (1) 1–28
Voermans, N.C., see van der Sluijs, B.M. (1) 101–109
Vondráček, P., see Vry, J. (4) 517–527
Vry, J., K. Gramsch, S. Rodger, R. Thompson, B.F. Steffensen, J. Rahbek, S. Doerken, A. Tassoni, M. de los Angeles Beytía, V. Guergueltcheva, T. Chamova, I. Tournev, A. Kostera-Pruszczyk, A. Kaminska, A. Lusakowska, L. Mrazova, L. Pavlovska, J. Strenkova, P. Vondráček, M. Garami, V. Karcagi, Á. Herczegfalvi, K. Bushby, H. Lochmüller and J. Kirschner, European Cross-Sectional Survey of Current Care Practices for Duchenne Muscular Dystrophy Reveals Regional and Age-Dependent Differences (4) 517–527
Waddell, L.B., see Punetha, J. (2) 209–225
Wahbi, K., see Marey, I. (2) 227–245
Walklet, E., K. Muse, J. Meyrick and T. Moss, Do Psychosocial Interventions Improve Quality of Life and Wellbeing in Adults with Neuromuscular Disorders? A Systematic Review and Narrative Synthesis (3) 347–362
Weis, J., see Bouhy, D. (2) 183–200
Weis, J., see Buchkremer, S. (2) 169–181
West, S.D., H. Lochmüller, J. Hughes, A. Atalaia, C. Marini-Bettolo, S.V. Baudouin and K.N. Anderson, Sleepiness and Sleep-related Breathing Disorders in Myotonic Dystrophy and Responses to Treatment: A Prospective Cohort Study (4) 529–537
Willems, M., see Grotto, S. (4) 487–495
Yaou, R.B., see Marey, I. (2) 227–245
Ylikallio, E., M. Auranen, I. Mahjneh, A. Lamminen, M. Kousi, A.-L. Träskelin, T. Muurinen, M. Löfberg, T. Salmi, A. Paetau, A.-E. Lehesjoki, P. Piirilä and S. Kiuru-Enari, Decreased Aerobic Capacity in ANO5-Muscular Dystrophy (4) 475–485
Yokota, T., see Rodrigues, M. (1) 29–48
Zhang, J., see Carver, M.P. (3) 381–393
Ziat, E., K. Mamchaoui, M. Beuvin, I. Nelson, F. Azibani, S. Spuler, G. Bonne and A.T. Bertrand, FHL1B Interacts with Lamin A/C and Emerin at the Nuclear Lamina and is Misregulated in Emery-Dreifuss Muscular Dystrophy (4) 497–510
Zins, J.G., see Lowe, J. (3) 395–404
